These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12858988)

  • 1. Rate-decreasing effects of the atypical neuroleptic risperidone attenuated by conditions of reinforcement in a woman with mental retardation.
    Yoo JH; Williams DC; Napolitano DA; Peyton RT; Baer DM; Schroeder SR
    J Appl Behav Anal; 2003; 36(2):245-8. PubMed ID: 12858988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone and explosive aggressive autism.
    Horrigan JP; Barnhill LJ
    J Autism Dev Disord; 1997 Jun; 27(3):313-23. PubMed ID: 9229261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study.
    Troost PW; Althaus M; Lahuis BE; Buitelaar JK; Minderaa RB; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):561-73. PubMed ID: 17069545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism.
    Hellings JA; Zarcone JR; Crandall K; Wallace D; Schroeder SR
    J Child Adolesc Psychopharmacol; 2001; 11(3):229-38. PubMed ID: 11642473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A crossover study of risperidone in children, adolescents and adults with mental retardation.
    Hellings JA; Zarcone JR; Reese RM; Valdovinos MG; Marquis JG; Fleming KK; Schroeder SR
    J Autism Dev Disord; 2006 Apr; 36(3):401-11. PubMed ID: 16596465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risperidone-associated urinary incontinence in patients with autistic disorder with mental retardation.
    Kumazaki H; Watanabe K; Imasaka Y; Iwata K; Tomoda A; Mimura M
    J Clin Psychopharmacol; 2014 Oct; 34(5):624-6. PubMed ID: 25118082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders.
    Hellings JA; Zarcone JR; Valdovinos MG; Reese RM; Gaughan E; Schroeder SR
    J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):885-92. PubMed ID: 16379508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroleptic malignant syndrome with risperidone.
    Levin GM; Lazowick AL; Powell HS
    J Clin Psychopharmacol; 1996 Apr; 16(2):192-3. PubMed ID: 8690838
    [No Abstract]   [Full Text] [Related]  

  • 9. Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults.
    Khan BU
    J Autism Dev Disord; 1997 Aug; 27(4):479-89. PubMed ID: 9261670
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls.
    Soyka M; Winter C; Kagerer S; Brunnauer M; Laux G; Möller HJ
    J Psychiatr Res; 2005 Jan; 39(1):101-8. PubMed ID: 15504428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reinforcing efficacy of interactions with preferred and nonpreferred staff under progressive-ratio schedules.
    Jerome J; Sturmey P
    J Appl Behav Anal; 2008; 41(2):221-5. PubMed ID: 18595285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risperidone-induced double incontinence.
    Hergüner S; Mukaddes NM
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1085-6. PubMed ID: 18387724
    [No Abstract]   [Full Text] [Related]  

  • 13. Weight gain with risperidone among patients with mental retardation: effect of calorie restriction.
    Cohen S; Glazewski R; Khan S; Khan A
    J Clin Psychiatry; 2001 Feb; 62(2):114-6. PubMed ID: 11247096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone.
    Aman MG; Gharabawi GM;
    J Clin Psychiatry; 2004 Sep; 65(9):1197-210. PubMed ID: 15367046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risperidone use in child and adolescent psychiatric patients].
    Chevreuil C; Reymann JM; Frémaux T; Polard E; Séveno T; Bentué-Ferrer D
    Therapie; 2008; 63(5):359-75. PubMed ID: 19154706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.
    Research Units on Pediatric Psychopharmacology Autism Network
    Am J Psychiatry; 2005 Jul; 162(7):1361-9. PubMed ID: 15994720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
    Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triazolam and ethanol effects on human matching-to-sample performance vary as a function of pattern size and discriminability.
    Roache JD; Spiga R; Burt DB
    Drug Alcohol Depend; 1993 May; 32(3):219-29. PubMed ID: 8348874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Possibilities and limits of treatment of aggressive behavior in patients with mental retardation with risperidone].
    Hässler F; Buchmann J; Bohne S
    Nervenarzt; 2002 Mar; 73(3):278-82. PubMed ID: 11963264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.